Browse more cannabis research, findings, methods, and limitations.
Maternal omega-3 supplementation reversed THC-induced fetal growth restriction and cardiac deficits in rat offspring, possibly through reduced endocannabinoid signaling.
COVID-related stress predicted cannabis vaping in high schoolers two years later, mediated through increased susceptibility to vaping.
In 6,049 participants from the ALSPAC cohort, childhood externalizing disorders at age 10 predicted multiple problematic cannabis use trajectories from ages 15-24.
Cannabis disrupted brain connectivity patterns in all users, but chronic users showed persistent network changes even when sober—suggesting lasting brain adaptation.
A mobile app successfully collected real-time passive and active data from 95 veterans with PTSD and cannabis use over 3 months, with 92% passive and 68% active data rates.
Adults with opioid addiction and chronic pain who added a daily THC:CBD capsule to their buprenorphine treatment reported less pain and better sleep after three months, though opioid cravings did not significantly change.
Year-long interviews with people on opioid addiction treatment found they reported less pain, better mood and sleep, and fewer drug cravings from medical cannabis, though cost and appetite changes were concerns.
A survey of 11,479 cannabis growers across 18 countries found about 1 in 4 used chemical additives, but rates appear to be declining over the past decade.
Among 772 heart attack patients across 39 French hospitals, 11% tested positive for cannabis and had over 3 times the odds of serious in-hospital complications like cardiac arrest or death.
An Australian national survey found 6.2% of cannabis users met criteria for high-risk use, with daily consumption, starting before age 15, and psychological distress as the strongest predictors.
A lab study found recreational drug users, including cannabis users, recalled fewer specific personal memories than non-users, even after accounting for sleep, health, and alcohol.
A two-year study of 3,278 Southern California teens found that how they perceived their neighborhood was a stronger predictor of cannabis and nicotine vaping than census-based measures of disadvantage.
Cannabis driving laws are being set without adequate science—we need comprehensive THC pharmacokinetic data to connect blood levels to actual impairment.
A pharmacokinetic model showed that current blood THC limits for driving (1, 2, or 5 ng/mL) may be unreliable for people who consume cannabis orally, with the 1 ng/mL limit most prone to false positives.
A three-year brain imaging study found heavy cannabis users developed significant thinning in a brain region crucial for decision-making, with greater thinning linked to more severe use patterns.
A longitudinal study of 4,769 US teens found that those spending 30 minutes to 3 hours daily on social media had the highest odds of later marijuana and alcohol use.
A meta-analysis of 26 animal studies found cannabinoids significantly reduced brain damage after stroke, with CBD showing the most consistent benefits across multiple protective pathways.
Analysis of over 7,000 US adults found that those who sat for 6-8 hours daily were 22% less likely to report marijuana use, with the strongest pattern among Hispanic adults.
A massive meta-analysis of 359 animal experiments confirmed that adolescent cannabinoid exposure consistently produces schizophrenia-like behavioral changes including memory impairment, social deficits, and disrupted sensory gating.
Focus groups with 28 chronic pain patients found widespread uncertainty about medical cannabis effectiveness, dosing, safety, and cost, whether or not they had tried it.
Machine learning identified a brain connectivity pattern that predicted problem cannabis use across three independent samples, including college students, European teens, and treatment-seeking adults.
Mice given THC during adolescence had reduced sperm counts and testicular damage as young adults, while the same exposure in adulthood caused milder reproductive effects.
CBD protected dopamine neurons and delayed motor symptoms in a progressive Parkinson mouse model, with preventive treatment working better than treatment started after symptom onset.
Independent testing of 74 Colorado cannabis products found flower labels consistently overstated THC content, sometimes beyond the 15% legally allowed variance.
The 2023 National Youth Tobacco Survey found home smoking exposure was the strongest predictor of teen tobacco and cannabis use, while mental stress was key for LGBTQ+ middle schoolers.
An EMA study found that college students' morning willingness and social motives predicted same-day simultaneous alcohol and cannabis use, creating a window for potential digital interventions.
A survey of nearly 2,400 Australian medical cannabis patients found those using specialized cannabis clinics were less satisfied than those treated in general healthcare settings, especially regarding consultation quality and costs.
Analysis of nearly 69,000 suicide deaths found that more permissive cannabis policies and cannabis involvement were both linked to higher odds of opioid involvement in these deaths.
A study of people with anxiety found that baseline inflammation levels influenced whether different cannabis products improved mood and sleep, with CBD-dominant products showing the most reliable benefits.
An eye-tracking study found specific, concrete cannabis warning labels captured more attention and improved risk recognition among young adults compared to generic labels.
A study of 157 young people in opioid addiction treatment found cannabis use disorder predicted shorter retention, while depression and PTSD were linked to staying in treatment longer.
Analysis of 105 datasets found THC and CBD have largely different molecular effects: CBD consistently suppressed inflammation while THC primarily affected neuronal signaling.
A review of expert recommendations for monitoring cannabis legalization impacts reveals a wide gap between what should be tracked and what actually is.
A survey of 4,134 daily cannabis users found older adults used less potent products, but their risk of cannabis use disorder per milligram of THC was similar to younger users.
A trial of 150 participants found computer-based motivational interviews generated similar "change talk" about marijuana as face-to-face sessions, but only face-to-face showed a trend toward reducing actual use.
A meta-analysis of 51 studies and 21 million pregnancies found cannabis use was associated with 52-75% higher odds of preterm birth, low birth weight, and small babies, even after accounting for tobacco use.
IBD patients who used cannabis had longer endoscopic procedures and more inflammation on evaluation compared to matched non-users, raising questions about whether cannabis masks symptoms without treating disease.
A small controlled trial of THC/CBD capsules found no evidence that cannabinoids reduced essential tremor amplitude, despite widespread anecdotal reports of cannabis helping.
A Nature Reviews Neuroscience review mapped how the brain's endocannabinoid system regulates anxiety and stress through specific neural circuits, suggesting endocannabinoid-boosting drugs as future treatments.
A survey of 166 young adults found that Delta-9 THC users had 20 times the odds of also using Delta-8, with complex and sometimes contradictory risk perception patterns.
Snapchat's AI chatbot freely discussed Delta-8 THC despite blocking other drug terms, providing favorable but uncited information to its predominantly young user base.
Among 1,968 young adult cannabis users, those who also used derived products like Delta-8 reported more negative consequences than cannabis-only users, with coping and enhancement motives driving co-use.
A review of 22 US states with legal cannabis found most had social equity programs, but only 4 directed tax revenue back to equity initiatives and programs varied widely in scope.
A survey of 4,031 young adults found 70% incorrectly believed derived cannabis products like Delta-8 were safety-tested and 59% thought they were FDA-approved.
Analysis of four US cannabis companies found nearly $500K spent on 399 unique ads, primarily through online displays on news websites using GIF-based visuals.
Young smokers with cannabis dependence perceived fewer downsides to smoking, and younger people preferred app-based cessation therapy over face-to-face.
Rat study found cannabis-induced overeating works by triggering more frequent meals through the brain's orexin system, and blocking this pathway eliminated the munchies effect.
Testing of 127 Australian street cannabis samples found average 12% THC with almost no CBD, and users could not accurately judge potency from their experience.
A randomized trial of 66 adults found that a brief (~16-day) mindfulness program did not reduce cannabis use, cravings, or quantity compared to relaxation or monitoring alone.
A review found unregulated cannabinoid vaping products contain high concentrations and produce potentially toxic heating byproducts called quinones that may damage lung tissue.